Special Issue

Innovative 3D Printing Techniques for Personalized Anti-Cancer Therapy

Message from the Guest Editors

Three-dimensional printing technology has been widely studied in implants, medical devices, tissue engineering, and drug delivery systems due to its advantages in personalized medicine, such as anti-cancer therapy research, tissue engineering applications, and regenerative medicine. As a leading cause of death worldwide, cancer encompasses a large group of diseases in which cellular changes cause uncontrollable growth and spread. Breast, lung, bowel, and prostate cancers are the most common causes of death from cancer. Therefore, the diagnosis, treatment, and drug development of cancer have drawn much attention. Unfortunately, many anti-cancer therapeutic drugs exhibit severe side effects, low bioavailability, and high toxicity. In recent years, 3D printing technology has played an important role in personalized anti-cancer therapy, including in vitro cancer model development, flexible fabrications of implantable drug delivery systems, various dosage forms with modulated anti-cancer drug release kinetics, and personalized surgical instruments. This Special Issue aims to focus on the advancements of 3D printing technologies in personalized anti-cancer therapy.

Guest Editors

Dr. Kejing Shi

Department for Bioscience, School of Health, Sport and Bioscience, University of East London, Water Lane, London E15 4LZ, UK

Dr. Hyunah Cho

College of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA

Deadline for manuscript submissions

20 August 2025

Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed

mdpi.com/si/231645

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics

Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed

mdpi.com/journal/pharmaceutics

MDPI

About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).